Versant Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Versant Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,091	Closed	-$4K	–	1674
2020 Q1	$4K	Buy	+1,091	New	+$4.7K	﹤0.01%	878
2019 Q2	–	Sell	-74	Closed	–	–	1846
2019 Q1	$0	Sell	74 -45	-38%	-$204	﹤0.01%	1823
2018 Q4	$0	Buy	119 +45	+61%	+$229	﹤0.01%	1732
2018 Q3	$0	Buy	+74	New	+$568	﹤0.01%	1717
2018 Q2	–	Sell	-24	Closed	–	–	1709
2018 Q1	$0	Buy	+24	New	+$160	﹤0.01%	1733

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Versant Capital Management's PGNX Position: Q2 2020 in Review

Versant Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 1,091 shares — an estimated $4K sold.

Versant Capital Management first reported a position in PGNX in Q1 2018 and held it in 5 quarters. The position peaked at $4K in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Versant Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Versant Capital Management sold 1,091 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $4K.
Versant Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2018 and held it in 5 quarters.
Versant Capital Management's Progenics Pharmaceuticals Inc position peaked at $4K in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Versant Capital Management's 13F filing for Q2 2020, filed 16 Jul 2020.